

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Apollo invests approx Rs 40 Cr to build Lymphedema Clinic for women's healthcare

11 August 2026 | News

A first-of-its-kind multidisciplinary programme brings global standards of lymphatic care to India



Apollo Athenaa, Asia's first dedicated women cancer centre by Apollo Hospitals, has announced the launch of India's first one stop comprehensive Lymphedema Clinic in Delhi, accredited by the Lymphatic Education & Research Network (LE&RN)—an internationally recognised non-profit organisation dedicated to advancing education, research and advocacy for lymphatic diseases—setting a new benchmark in the management of cancer-related lymphedema.

Designed around internationally recognised standards of care, the clinic (built with an investment of approx Rs 40 crore) brings together specialised surgeons, lymphedema therapists, nurses, dermatologists and rehabilitation experts under a single multidisciplinary programme, offering comprehensive care spanning prevention, early diagnosis, advanced microsurgery, rehabilitation and lifelong follow-up.

India is estimated to have over one million people living with lymphedema. Of these, an estimated 400,000–600,000 are living with cancer-related lymphedema, with 30,000–50,000 new cases developing annually. As cancer survival rates continue to improve, this burden is expected to rise, underscoring the urgent need for dedicated multidisciplinary lymphedema services.

Women undergoing breast and gynaecological cancer treatment remain among the most vulnerable, as lymph node removal and radiation therapy can permanently disrupt lymphatic drainage, resulting in chronic swelling, recurrent infections, reduced mobility and a significant impact on long-term quality of life.

Up to 20% to 42% of women develop arm lymphedema after breast cancer surgery, and roughly 31% to 37% of survivors of gynecological cancers experience lower-limb lymphedema.

Despite this growing burden, access to specialised multidisciplinary lymphedema care remains limited in India, with patients often navigating fragmented treatment pathways that delay intervention and compromise long-term outcomes.